A Phase 2 interventional study of BI 690517 and Placebo to BI 690517 in Kidney Disease, Chronic, sponsored by Boehringer Ingelheim. Completed at 203 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.
Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 4 in phase 2, and was the 5th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
Ann & Robert H Lurie Children's Hospital of Chicago · Sites in United States
Ages 12–25
VA Office of Research and Development · Sites in United States
Ages 19+
Washington D.C. Veterans Affairs Medical Center · Sites in United States
Ages 19–90
Baylor Research Institute · Sites in United States
Ages 18–84
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 3 · Phase 4 9
First in 2019; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 714 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 77 across the 20 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim: none open now, 4 under way, 2 of them phase 3. Of 9 finished, 7 (78%) have results posted.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 6th registered.
Boehringer Ingelheim’s Renal Insufficiency, Chronic studies by the year they started, since 2012.
2 of the studies testing empagliflozin in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, from their registry updates:
Among Boehringer Ingelheim’s 13 in Renal Insufficiency, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study.
The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin.
In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine.
In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine.
Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call.
Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria to be assessed before second randomisation (start of Treatment Period):
Exclusion criteria
Further criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin
Drug: Placebo to empagliflozin
Drug: BI 690517 · Drug: Empagliflozin
Drug: BI 690517 · Drug: Empagliflozin
Drug: BI 690517 · Drug: Empagliflozin
Drug: Placebo to BI 690517 · Drug: Empagliflozin
Drug: BI 690517 · Drug: Placebo to empagliflozin
Drug: BI 690517 · Drug: Placebo to empagliflozin
Drug: BI 690517 · Drug: Placebo to empagliflozin
Drug: Placebo to BI 690517 · Drug: Placebo to empagliflozin
Film-coated tablets
Also known as: Vicadrostat
Film-coated tablets
Empagliflozin
Placebo to empagliflozin
Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients
The adjusted mean change (95% confidence interval) in log transformed FMV UACR from baseline at 14 weeks is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients
Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for all patients is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin
The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin
Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin
The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin
Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF)
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 week. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF)
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.
Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
The trial included two randomisations, R1 and R2. At first randomisation R1, patients were 1:1 randomised to a run-in period of 8 weeks and received 10 mg empagliflozin or placebo matching empagliflozin. The run-in period was followed by randomisation R2 at which patients were 1:1:1:1 randomized to a treatment period of 14 weeks to receive one of three doses of BI 690517 or placebo matching BI 690517 in combination with the background medication assigned in the randomized run-in period.
| Milestone | Run-in Period: 10 mg Empagliflozin | Run-in Period: Placebo to Empagliflozin 10 mg | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 356 | 358 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated with empagliflozin 10 mg or placebo matching empagliflozin 10 mg | 356 | 357 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 332 | 330 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 24 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other reason but not sponsor termination | 14 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No reason available | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Burden of study procedures | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Change of residence | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Run-in Period: 10 mg Empagliflozin | Run-in Period: Placebo to Empagliflozin 10 mg | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 332 | 330 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 298 | 286 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 34 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet additional inclusion/exclusion criteria for treatment period | 34 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Run-in Period: 10 mg Empagliflozin | Run-in Period: Placebo to Empagliflozin 10 mg | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 298 | 288 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not complete the run-in period and was randomized to treatment period | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed run-in period and randomized to treatment period | 298 | 286 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 298 | 288 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Run-in Period: 10 mg Empagliflozin | Run-in Period: Placebo to Empagliflozin 10 mg | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 76 | 74 | 74 | 74 | 71 | 72 | 72 | 73 |
| Treated with bi 690517 or placebo matching bi 690517 | 0 | 0 | 76 | 73 | 74 | 74 | 70 | 71 | 72 | 73 |
| Completed | 0 | 0 | 63 | 50 | 55 | 58 | 61 | 54 | 48 | 66 |
| Not completed | 0 | 0 | 13 | 24 | 19 | 16 | 10 | 18 | 24 | 7 |
| Withdrew: Reason missing | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other but not sponsor termination | 0 | 0 | 8 | 6 | 6 | 7 | 5 | 8 | 7 | 2 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: No reason available | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Burden of study procedures | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Change of residence | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 4 | 16 | 12 | 6 | 4 | 8 | 16 | 5 |
| Withdrew: Not treated with study drug | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
The adjusted mean change (95% confidence interval) in log transformed FMV UACR from baseline at 14 weeks is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
| log (milligram/gram) | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients | -0.235 (-0.355 to -0.114) | -0.553 (-0.681 to -0.425) | -0.487 (-0.616 to -0.357) | -0.066 (-0.184 to 0.051) |
Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for all patients is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
| percent change of FMV UACR | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients | -20.9 (-29.9 to -10.8) | -42.5 (-49.4 to -34.6) | -38.5 (-46.0 to -30.0) | -6.4 (-16.8 to 5.3) |
The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
| log (milligram/gram) | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin | -0.254 (-0.441 to -0.068) | -0.496 (-0.693 to -0.299) | -0.455 (-0.666 to -0.245) | -0.027 (-0.208 to 0.155) |
Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
| percent change of FMV UACR | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin | -22.4 (-35.6 to -6.5) | -39.1 (-50.0 to -25.8) | -36.6 (-48.6 to -21.7) | -2.6 (-18.8 to 16.8) |
The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
| log (milligram/gram) | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin | -0.210 (-0.366 to -0.055) | -0.614 (-0.783 to -0.445) | -0.516 (-0.675 to -0.357) | -0.112 (-0.264 to 0.040) |
Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
| percent change of FMV UACR | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin | -19.0 (-30.6 to -5.4) | -45.9 (-54.3 to -35.9) | -40.3 (-49.1 to -30.0) | -10.6 (-23.2 to 4.1) |
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation | 40 | 73 | 66 | 24 |
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder | 40 | 62 | 57 | 23 |
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
| Participants | BI 690517 3 mg | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF) | 45 | 67 | 73 | 31 |
Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis | 40 | 62 | 57 | 23 |
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation | 19 | 31 | 30 | 10 |
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder | 19 | 28 | 25 | 9 |
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF) | 22 | 31 | 32 | 14 |
Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis | 19 | 28 | 25 | 9 |
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation | 21 | 42 | 36 | 14 |
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder | 21 | 34 | 32 | 14 |
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward | 23 | 36 | 41 | 17 |
Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis | 21 | 34 | 32 | 14 |
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 week. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation | 68 | 82 | 81 | 46 |
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder | 67 | 71 | 70 | 44 |
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF) | 67 | 87 | 85 | 53 |
Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
| Participants | 3 mg BI 690517 | 10 mg BI 690517 | 20 mg BI 690517 | Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis | 67 | 71 | 70 | 44 |
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation | 33 | 35 | 39 | 22 |
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder | 32 | 32 | 32 | 20 |
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF) | 28 | 41 | 41 | 25 |
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation | 35 | 47 | 42 | 24 |
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder | 35 | 39 | 38 | 24 |
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward | 39 | 46 | 44 | 28 |
Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
| Participants | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis | 32 | 32 | 32 | 20 |
Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.
| Participants | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 |
|---|---|---|---|---|
| UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis | 35 | 39 | 38 | 24 |
Collected over Run-in period: From first study drug administration in the run-in period until end of the residual effect period (REP) (i.e., 7 days), up to 9 weeks. Treatment period: From first study drug administration in the treatment period until end of REP (i.e. 7 days), up to 15 weeks. All-Cause Mortality for treatment period: From study drug administration in the treatment period until end of the follow-up period, up to 18 weeks. Continues in the description.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Period: 10 mg Empagliflozin | 0/356 (0%) | 9/356 (2.5%) | 17/356 (4.8%) |
| Run-in Period: Placebo to Empagliflozin 10 mg | 2/357 (0.6%) | 20/357 (5.6%) | 15/357 (4.2%) |
| Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | 1/76 (1.3%) | 4/76 (5.3%) | 11/76 (14.5%) |
| Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | 1/73 (1.4%) | 7/73 (9.6%) | 20/73 (27.4%) |
| Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | 0/74 (0%) | 5/74 (6.8%) | 19/74 (25.7%) |
| Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | 2/74 (2.7%) | 7/74 (9.5%) | 13/74 (17.6%) |
| Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | 0/70 (0%) | 3/70 (4.3%) | 15/70 (21.4%) |
| Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | 1/71 (1.4%) | 4/71 (5.6%) | 16/71 (22.5%) |
| Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | 1/72 (1.4%) | 6/72 (8.3%) | 25/72 (34.7%) |
| Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 | 0/73 (0%) | 3/73 (4.1%) | 9/73 (12.3%) |
| Event | Run-in Period: 10 mg Empagliflozin | Run-in Period: Placebo to Empagliflozin 10 mg | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiencyEndocrine disorders | 1/356 | 0/357 | 0/76 | 2/73 | 1/74 | 1/74 | 1/70 | 0/71 | 2/72 | 0/73 |
| Acute kidney injuryRenal and urinary disorders | 1/356 | 2/357 | 0/76 | 1/73 | 0/74 | 0/74 | 0/70 | 1/71 | 2/72 | 1/73 |
| Cardiac failure congestiveCardiac disorders | 0/356 | 0/357 | 0/76 | 0/73 | 0/74 | 0/74 | 1/70 | 0/71 | 0/72 | 0/73 |
| Subcapsular renal haematomaRenal and urinary disorders | 0/356 | 0/357 | 0/76 | 0/73 | 0/74 | 0/74 | 1/70 | 0/71 | 0/72 | 0/73 |
| Sudden deathGeneral disorders | 0/356 | 0/357 | 0/76 | 0/73 | 0/74 | 1/74 | 0/70 | 1/71 | 0/72 | 0/73 |
| Dengue feverInfections and infestations | 0/356 | 0/357 | 0/76 | 0/73 | 0/74 | 0/74 | 0/70 | 1/71 | 0/72 | 0/73 |
| PneumoniaInfections and infestations | 1/356 | 1/357 | 1/76 | 1/73 | 0/74 | 1/74 | 0/70 | 1/71 | 0/72 | 1/73 |
| SepsisInfections and infestations | 0/356 | 1/357 | 0/76 | 0/73 | 0/74 | 0/74 | 0/70 | 1/71 | 0/72 | 0/73 |
| Ischaemic cerebral infarctionNervous system disorders | 0/356 | 0/357 | 0/76 | 0/73 | 0/74 | 0/74 | 0/70 | 1/71 | 0/72 | 0/73 |
| Intracardiac thrombusCardiac disorders | 0/356 | 0/357 | 0/76 | 0/73 | 0/74 | 0/74 | 0/70 | 0/71 | 1/72 | 0/73 |
| Event | Run-in Period: 10 mg Empagliflozin | Run-in Period: Placebo to Empagliflozin 10 mg | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 |
|---|---|---|---|---|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 8/356 | 8/357 | 5/76 | 11/73 | 7/74 | 5/74 | 8/70 | 7/71 | 17/72 | 4/73 |
| Glomerular filtration rate decreasedInvestigations | 4/356 | 1/357 | 4/76 | 8/73 | 7/74 | 2/74 | 1/70 | 7/71 | 6/72 | 3/73 |
| Cortisol decreasedInvestigations | 0/356 | 1/357 | 2/76 | 1/73 | 0/74 | 1/74 | 3/70 | 4/71 | 2/72 | 0/73 |
| HypotensionVascular disorders | 2/356 | 0/357 | 0/76 | 4/73 | 2/74 | 1/74 | 1/70 | 0/71 | 0/72 | 0/73 |
| Upper respiratory tract infectionInfections and infestations | 4/356 | 5/357 | 1/76 | 1/73 | 4/74 | 4/74 | 2/70 | 1/71 | 3/72 | 2/73 |
Randomised Set (RS): This patient set included all entered and randomised patients based on the treatment groups they were randomised to at the randomisation prior to the treatment period (i.e. at second randomisation (R2)), regardless of being treated by BI 690517 or not.
| Age, Continuous(Years) | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 65.4 ± 11.2 | 64.4 ± 12.3 | 61.8 ± 12.2 | 63.4 ± 10.3 | 64.4 ± 11.8 | 64.8 ± 9.9 | 64.3 ± 10.7 | 62.3 ± 11.4 | 63.8 ± 11.3 |
| Sex: Female, Male(Participants) | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 27 | 30 | 20 | 31 | 20 | 23 | 27 | 18 | 196 |
| Male | 49 | 44 | 54 | 43 | 51 | 49 | 45 | 55 | 390 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 25 | 21 | 12 | 20 | 22 | 21 | 18 | 24 | 163 |
| Not Hispanic or Latino | 51 | 53 | 62 | 54 | 49 | 51 | 54 | 49 | 423 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 2 | 2 | 2 | 3 | 1 | 13 |
| Asian | 17 | 27 | 20 | 19 | 23 | 15 | 19 | 16 | 156 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 9 | 6 | 7 | 10 | 3 | 9 | 9 | 10 | 63 |
| White | 49 | 35 | 45 | 42 | 42 | 45 | 40 | 44 | 342 |
| More than one race | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine Albumin Creatinine Ratio (UACR) at baseline(milligram/gram) | Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 | Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 | Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 780.3 ± 828.8 | 740.8 ± 915.0 | 695.4 ± 748.0 | 801.4 ± 1132.3 | 934.0 ± 1363.6 | 646.2 ± 685.2 | 785.0 ± 885.7 | 684.4 ± 715.1 | 757.9 ± 930.5 |
Showing the first 100 of 203 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Once the time frame criteria given under number 4 are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.mystudywindow.com
Ran from Jan 2022 to primary completion in Jun 2023, 17 months.
Results were first posted in Aug 2024, 1 year 2 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 17 months is below that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vicadrostat · Empagliflozin
Renal Insufficiency, Chronic →